PSMA targeted radiotherapy medicine and preparation method thereof
The invention features a novel precursor provided for radioisotope labeling with ligands for specific binding of prostate-specific membrane antigen (PSMA) for prostate cancer diagnosis and treatment, and the pharmacophore of a PSMA inhibitor composed of three molecules of glutamic acid, urea and lysine is provided with three variable linkers based on pharmacological activity of the PSMA inhibitor for labeling with radioactive nucleus Ga-67, Ga-68, In-111, Lu-177, Cu-64, or Y-90 through a chelating agent for imaging analysis of human tumor models of prostate cancer and serving as a PSMA-targeted radioligand therapy for prostate cancer diseases.
1. A PSMA inhibitor of structure
wherein P1 is selected from the group consisting of
P2 is selected from the group consisting of
and P3 is selected from the group consisting of
2. The PSMA inhibitor of claim 1 further comprising a radionuclide selected from the group consisting of Ga-68, Ga-67, In-111, Cu-64, Lu-177, and Y-90.
3. The PSMA inhibitor structure of claim 1 selected from the group consisting of